Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 4, 2013, Pages 1065-1072

  Zhang, Dong Sheng ^a   Wang, De Shen ^a   Wang, Zhi Qiang ^a   Wang, Feng Hua ^a   Luo, Hui Yan ^a   Qiu, Miao Zhen ^a   Wang, Feng ^a   Li, Yu Hong ^a   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Chemotherapy; Gemcitabine; nab paclitaxel; Pancreatic ductal adenocarcinoma; Phase I II study

Indexed keywords

GEMCITABINE; PACLITAXEL; 130 NM ALBUMIN BOUND PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINESE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; MIDDLE AGED; MORTALITY; PANCREAS TUMOR;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PANCREATIC NEOPLASMS;

MLCS; MLOWN;

EID: 84878870926     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2102-4     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Raimondi S, Maisonneuve P, Lowenfels AB (2009) Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6:699-708
3. Burris HR, Moore MJ, Andersen J, Green MR, Rothenberg ML et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
4. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
5. Wang DS, Chen DL, Ren C, Wang ZQ, Qiu MZ et al (2012) ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer 131:461-468
6. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS et al (2012) Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 29:3092-3100
7. Wang DS, Wang ZQ, Zhang L, Qiu MZ, Luo HY et al (2012) Are risk factors associated with outcomes in pancreatic cancer? PLoS ONE 7:e41984
8. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS et al (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548-4554
9. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ et al (2010) Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877-4883
10. Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG (2005) Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 72:267-272 (Pubitemid 40342998)
11. Koukourakis MI, Giatromanolaki A, Brekken RA, Sivridis E, Gatter KC et al (2003) Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 63:5376-5380 (Pubitemid 37139854)
12. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M (1999) Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 30:339-344 (Pubitemid 29125155)
13. Demeure MJ, Stephan E, Sinari S, Mount D, Gately S et al (2012) Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. Ann Surg 255:140-146
14. Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP et al (2012) nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2:260-269
15. Miyahara T, Mochinaga S, Kimura S, Aragane N, Yakabe T et al (2013) Effects of tumor type, degree of obesity, and chemotherapy regimen on chemotherapy dose intensity in obese cancer patients. Cancer Chemother Pharmacol 71:175-182
16. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ et al (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30:1553-1561
17. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL et al (2002) Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038-1044 (Pubitemid 34517637)
18. Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA et al (2007) Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 60:759-766 (Pubitemid 47247287)
19. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684-692 (Pubitemid 30078550)
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
21. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
22. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C (2008) Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82 (Pubitemid 351552578)
23. Burris HR, Moore MJ, Andersen J, Green MR, Rothenberg ML et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
24. Desai N, Trieu V, Yao Z, Louie L, Ci S et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324 (Pubitemid 43342524)